ERT eCOA Solution Assists in Migraine Study

September 19, 2016

ERT has announced that its electronic Clinical Outcome Assessment (eCOA) solution has assisted CoLucid Pharmaceuticals during its Phase III migraine drug study.

ERT has announced that its electronic Clinical Outcome Assessment (eCOA) solution has assisted CoLucid Pharmaceuticals during its Phase III migraine drug study. Patients used the solution to record migraine occurrence and rate headache pain severity as well as other symptoms.

Read the full release here

Related Content:

News